896700-07-5
896700-07-5
Chemical Structure
NCGC00138783 free base
- CAS No.: 896700-07-5
- Formula:C26H26FN7OS
- Molecular Weight:503.59
IUPAC Name: 2-((2-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)thio)-N-(4-fluorophenyl)butanamide
InChIKey: PGGYBDUANIHLIU-UHFFFAOYSA-N
SMILES: O=C(C(CC)SC1=NC2=C(C3=NC(CCC4=C(C)NN=C4C)=NN13)C=CC=C2)NC5=CC=C(C=C5)F
Biological Activity: NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NCGC00138783 free base | NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Junqiao Zhu, et al. CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems. Medicine in Drug Discovery. 2022. 15:100139
- [2]. Bo Huang, et al. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Comput Struct Biotechnol J. 2021 Oct 1;19:5494-5503. [Content Brief]
